Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Proleukin®
( aldesleukin )Oncology -
Promacta®/Revolade®
( eltrombopag )Oncology -
Ritalin LA®
( methylphenidate HCl modified release )NeuroscienceAvailable in -
Ritalin®
( methylphenidate HCl )Neuroscience -
Rydapt®
( midostaurin )Oncology -
Sandostatin LAR®
( octreotide acetate )Oncology -
Sandostatin® SC
( octreotide acetate )Oncology -
Scemblix®
( asciminib )Oncology -
Seebri Breezhaler®
( glycopyrronium bromide )RespiratoryAvailable in